BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31959735)

  • 1.
    Li M; Lin A; Luo P; Shen W; Xiao D; Gou L; Zhang J; Guo L
    Aging (Albany NY); 2020 Jan; 12(2):1285-1303. PubMed ID: 31959735
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic impact of tumor mutation burden and the mutation in KIAA1211 in small cell lung cancer.
    Zhou M; Fan J; Li Z; Li P; Sun Y; Yang Y; Zhou X; Wang J; Wang Y; Qi H; Cai W; Dai X; Hirsch FR
    Respir Res; 2019 Nov; 20(1):248. PubMed ID: 31699089
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of p62/SQSTM1 sensitizes small-cell lung cancer cells to cisplatin-induced cytotoxicity by targeting NEDD9 expression.
    Xu L; Xu F; Kong Q; Yang T; Tan D; Zhang X; Li N; Zhao S; Zhao J; Li M
    Mol Carcinog; 2020 Aug; 59(8):967-979. PubMed ID: 32424979
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The identification of a two-gene prognostic model based on cisplatin resistance-related ceRNA network in small cell lung cancer.
    Zhang Y; Zhu Q; Qi J; Fu M; Xu A; Wang W; Wang H; Nie J; Hong B
    BMC Med Genomics; 2023 May; 16(1):103. PubMed ID: 37189142
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel mutation panel for predicting etoposide resistance in small-cell lung cancer.
    Qiu Z; Lin A; Li K; Lin W; Wang Q; Wei T; Zhu W; Luo P; Zhang J
    Drug Des Devel Ther; 2019; 13():2021-2041. PubMed ID: 31417239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of PI3K/AKT Pathway Is a Potential Mechanism of Treatment Resistance in Small Cell Lung Cancer.
    Jin Y; Chen Y; Tang H; Hu X; Hubert SM; Li Q; Su D; Xu H; Fan Y; Yu X; Chen Q; Liu J; Hong W; Xu Y; Deng H; Zhu D; Li P; Gong Y; Xia X; Gay CM; Zhang J; Chen M
    Clin Cancer Res; 2022 Feb; 28(3):526-539. PubMed ID: 34921019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High mutations in fatty acid metabolism contribute to a better prognosis of small-cell lung cancer patients treated with chemotherapy.
    Lyu Q; Zhu W; Wei T; Ding W; Cao M; Wang Q; Guo L; Luo P; Zhang J
    Cancer Med; 2021 Nov; 10(21):7863-7876. PubMed ID: 34564955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TSPAN12 promotes chemoresistance and proliferation of SCLC under the regulation of miR-495.
    Ye M; Wei T; Wang Q; Sun Y; Tang R; Guo L; Zhu W
    Biochem Biophys Res Commun; 2017 Apr; 486(2):349-356. PubMed ID: 28302484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ESRP1 regulates alternative splicing of CARM1 to sensitize small cell lung cancer cells to chemotherapy by inhibiting TGF-β/Smad signaling.
    Zheng M; Niu Y; Bu J; Liang S; Zhang Z; Liu J; Guo L; Zhang Z; Wang Q
    Aging (Albany NY); 2021 Jan; 13(3):3554-3572. PubMed ID: 33495408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [DDP-sensitivity-related genes in 10 lung cancer cell lines].
    Li CH; Cai L; Chen XS; Meng QW; Sui GJ
    Zhonghua Zhong Liu Za Zhi; 2008 Jun; 30(6):418-21. PubMed ID: 19024514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upregulation of the inwardly rectifying potassium channel Kir2.1 (KCNJ2) modulates multidrug resistance of small-cell lung cancer under the regulation of miR-7 and the Ras/MAPK pathway.
    Liu H; Huang J; Peng J; Wu X; Zhang Y; Zhu W; Guo L
    Mol Cancer; 2015 Mar; 14():59. PubMed ID: 25880778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ratio of Bcl-2/Bim as a predictor of cisplatin response provides a rational combination of ABT-263 with cisplatin or radiation in small cell lung cancer.
    Li H; Wang H; Deng K; Han W; Hong B; Lin W
    Cancer Biomark; 2019; 24(1):51-59. PubMed ID: 30614795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic based analyses reveal unique mutational profiling and identify prognostic biomarker for overall survival in Chinese small-cell lung cancer.
    Wang Y; Han X; Wang X; Sheng W; Chen Z; Shu W; Han J; Zhao S; Dai Y; Wang K; Shi W; Yang Z
    Jpn J Clin Oncol; 2019 Dec; 49(12):1143-1150. PubMed ID: 31612912
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The frequency and impact of FGFR1 amplification on clinical outcomes in Korean patients with small cell lung cancer.
    Park JS; Lee JS; Kim EY; Jung JY; Kim SK; Chang J; Kim DJ; Lee CY; Jung I; Kim JH; Kim HR; Moon YW; Kim HS; Cho BC; Shim HS
    Lung Cancer; 2015 Jun; 88(3):325-31. PubMed ID: 25819384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FOXM1 is required for small cell lung cancer tumorigenesis and associated with poor clinical prognosis.
    Liang SK; Hsu CC; Song HL; Huang YC; Kuo CW; Yao X; Li CC; Yang HC; Hung YL; Chao SY; Wu SC; Tsai FR; Chen JK; Liao WN; Cheng SC; Tsou TC; Wang IC
    Oncogene; 2021 Jul; 40(30):4847-4858. PubMed ID: 34155349
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of BRCA1, ERCC1, ATP7B, PKM2, TOPOI, TOPΟ-IIA, TOPOIIB and C-MYC genes in patients with small cell lung cancer (SCLC) who received first line therapy with cisplatin and etoposide.
    Karachaliou N; Papadaki C; Lagoudaki E; Trypaki M; Sfakianaki M; Koutsopoulos A; Mavroudis D; Stathopoulos E; Georgoulias V; Souglakos J
    PLoS One; 2013; 8(9):e74611. PubMed ID: 24058603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inferring the Evolution and Progression of Small-Cell Lung Cancer by Single-Cell Sequencing of Circulating Tumor Cells.
    Su Z; Wang Z; Ni X; Duan J; Gao Y; Zhuo M; Li R; Zhao J; Ma Q; Bai H; Chen H; Wang S; Chen X; An T; Wang Y; Tian Y; Yu J; Wang D; Xie XS; Bai F; Wang J
    Clin Cancer Res; 2019 Aug; 25(16):5049-5060. PubMed ID: 31113842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shp2 confers cisplatin resistance in small cell lung cancer via an AKT-mediated increase in CA916798.
    Yang X; Tang C; Luo H; Wang H; Zhou X
    Oncotarget; 2017 Apr; 8(14):23664-23674. PubMed ID: 28423588
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EPHA3 regulates the multidrug resistance of small cell lung cancer via the PI3K/BMX/STAT3 signaling pathway.
    Peng J; Wang Q; Liu H; Ye M; Wu X; Guo L
    Tumour Biol; 2016 Sep; 37(9):11959-11971. PubMed ID: 27101199
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.